Key facts
- This page summarizes David Dalgarno's Form 3 filing for Theseus Pharmaceuticals, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 06 Oct 2021, 19:00.
David Dalgarno - 06 Oct 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc.
- Reporting relationship
- Chief Technical Officer
- Issuer ticker
- N/A
- Reported as of
- 06 Oct 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Oct 2021, 19:00:46 UTC
- Next SEC filing
- 23 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bradford Dahms - Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Dalgarno filed Form 3 for Theseus Pharmaceuticals, Inc. on 06 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
THRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 388,324
- Date
- 06 Oct 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
THRX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 344,344
- Exercise price
- $0.3175
- Footnotes
- F1
THRX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 36,066
- Exercise price
- $4.03
- Footnotes
- F2
THRX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 06 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,549
- Exercise price
- $4.03
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer
Footnote F2
The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
Footnote F3
The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after May 27, 2021, subject to the Reporting Person's continuous service with the issuer.